Skip to content
OpenCapital
Get started

Cardiff Oncology CRDF Q2 2025 earnings

Reported July 29, 2025 · Before market open

Revenue$121.0KBeat by $11.6KDiluted EPS-$0.21Miss by $0.02
Revenue estimate$109.4K
EPS estimate-$0.19

Next report

Aug 4, 2026 (In 3 weeks)
Revenue estimate$62.8K
EPS estimate-$0.17

Versus estimates

Revenue

Q1 2026$41.0KMiss by $47.6KQ4 2025$243.0KBeat by $139.5KQ3 2025$120.0KBeat by $16.5K
Q2 2025$121.0KBeat by $11.6K
Q1 2025$109.0KBeat by $19.7KQ4 2024$151.0KBeat by $56.8K

Diluted EPS

Q1 2026-$0.18Miss by $0.05Q4 2025-$0.11Beat by $0.07Q3 2025-$0.17Beat by $0.03
Q2 2025-$0.21Miss by $0.02
Q1 2025-$0.20Miss by $0.01Q4 2024-$0.21Beat by $0.05

Ask the moment Cardiff Oncology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cardiff Oncology report Q2 2025 earnings?
Cardiff Oncology (CRDF) reported Q2 2025 earnings on July 29, 2025 before market open.
What were Cardiff Oncology's Q2 2025 revenue and EPS?
Cardiff Oncology reported revenue of $121.0K and diluted EPS of $-0.21 for Q2 2025.
Did Cardiff Oncology beat estimates in Q2 2025?
Revenue beat the consensus estimate of $109.4K by $11.6K. EPS missed the consensus estimate of $-0.19 by $0.02.
How did Cardiff Oncology's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 25.8% from $163.0K a year earlier and diluted EPS grew 19.2% from $-0.26.
Where can I find Cardiff Oncology's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-099610) directly on SEC EDGAR. The filing index links above go to sec.gov.